-
公开(公告)号：US08680111B2
公开(公告)日：2014-03-25
申请号：US13786106
申请日：2013-03-05
Applicant: Pfizer Inc.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: A01N43/42 , A61K31/44 , A01N43/02 , A61K31/335 , C07D471/00 , C07D491/00 , C07D498/00 , C07D513/00 , C07D515/00 , C07D313/00
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20160221989A1
公开(公告)日：2016-08-04
申请号：US14817416
申请日：2015-08-04
Applicant: Pfizer Inc.
Inventor： Sharanjeet Kaur Bagal , Kiyoyuki Omoto , Sarah Elizabeth Skerratt , Jingrong Jean Cui , Samantha Elizabeth Greasley , Indrawan James McAlpine , Asako Nagata , Sacha Ninkovic , Michelle Bich Tran-Dubé
IPC: C07D401/12 , A61K31/4439
CPC classification number: C07D401/12 , A61K31/4439
Abstract: The present invention relates to compounds of Formula I described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
Abstract translation: 本发明涉及本文所述的式I化合物及其药学上可接受的盐，以及它们在医药中的用途，特别是作为Trk拮抗剂。
-
Patent Agency Ranking
公开(公告)号：US20140135339A1
公开(公告)日：2014-05-15
申请号：US14156144
申请日：2014-01-15
Applicant: PFIZER INC.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D498/18 , C07D498/22
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
4.发明申请公开(公告)号：US20170197939A1
公开(公告)日：2017-07-13
申请号：US15300440
申请日：2015-04-01
Applicant: PFIZER INC.
Inventor： Sharanjeet Kaur Bagal , Jingrong Jean Cui , Samantha Elizabeth Greasley , Elizabeth Ann Lunney , Indrawan James McAlpine , Asako Nagata , Sacha Ninkovic , Kiyoyuki Omoto , Sarah Elizabeth Skerratt , Robert Ian Storer , Joseph Scott Warmus
IPC: C07D401/14 , A61K31/4439 , C07D401/12
CPC classification number: C07D401/14 , A61K31/4439 , C07D401/12
Abstract: The present invention relates to compounds of Formula I and their prodrugs and pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
-
公开(公告)号：US09328096B2
公开(公告)日：2016-05-03
申请号：US14705272
申请日：2015-05-06
Applicant: PFIZER INC
Inventor： Sharanjeet Kaur Bagal , Jingrong Jean Cui , Samantha Elizabeth Greasley , Elizabeth Ann Lunney , Indrawan James McAlpine , Asako Nagata , Sacha Ninkovic , Kiyoyuki Omoto , Sarah Elizabeth Skerratt , Robert Ian Storer , Joseph Scott Warmus
IPC: A61P35/00 , C07D413/14 , A61P29/00 , C07D405/14 , A61K31/4439 , C07D401/12 , C07D401/14
CPC classification number: C07D401/14 , C07D401/12 , C07D405/14 , C07D413/14
Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，其中取代基如本文所述，及其在药物中的用途，特别是作为TrkA拮抗剂。
-
公开(公告)号：US09133215B2
公开(公告)日：2015-09-15
申请号：US14156144
申请日：2014-01-15
Applicant: PFIZER INC.
Inventor： Simon Bailey , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/08 , C07D498/18 , C07D498/22 , C07D513/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Φ）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
公开(公告)号：US20130252961A1
公开(公告)日：2013-09-26
申请号：US13786106
申请日：2013-03-05
Applicant: PFIZER INC.
Inventor： Simon BAILEY , Benjamin Joseph Burke , Michael Raymond Collins , Jingrong Jean Cui , Judith Gail Deal , Robert Louis Hoffman , Qinhua Huang , Ted William Johnson , Robert Steven Kania , John Charles Kath , Phuong Thi Quy Le , Michele Ann McTigue , Cynthia Louise Palmer , Paul Francis Richardson , Neal William Sach
IPC: C07D498/08 , C07D513/18 , C07D498/22 , C07D498/18 , C07D491/18
CPC classification number: C07D498/08 , C07D273/02 , C07D413/04 , C07D413/14 , C07D491/08 , C07D491/18 , C07D498/18 , C07D498/22 , C07D513/18
Abstract: The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.
Abstract translation: 本发明涉及本文进一步定义的式（Phi）化合物及其药学上可接受的盐，涉及包含这些化合物和盐的药物组合物及其用途。 本发明的化合物和盐抑制间变性淋巴瘤激酶（ALK）和/或EML4-ALK，并且可用于治疗或改善异常细胞增殖性疾病如癌症。
-
-
-
-
-
-
Search Results
7
records
(took 0.049 seconds)
